SecBot SecBot
8-K ·Filed Aug 10, 2026

PALI

PALISADE BIO, INC.
NEUTRAL
Impact 5/10
Horizonmonths Processed3mo ago SEC0001357459-26-000017
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The stock will trade on Phase 2 execution milestones rather than financial results. Key catalysts to monitor: first patient enrollment in ASCENTRA-UC (expected 2H 2026), IND submission for ASCENTRA-CD (2H 2026), and any early efficacy signals from the Phase 2 program. The $125M cash runway removes near-term financing risk but the pre-revenue profile means binary Phase 2 readout risk dominates.

DirectionNeutral
Confidencehigh
Horizonmonths

PALI-2108

● Neutral Named in this 8-K
Impact
Phase
Phase 2b
Time to market
If Phase 2b succeeds, PALI-2108 would need to advance to Phase 3 trials and then file for FDA approval, a process that typically takes several more years. The earliest potential approval would likely be 2029-2030 at the earliest, assuming successful trials.
Next catalyst
None dated

What to watchThe next major catalyst is the Phase 2b ASCENTRA-UC topline data expected in Q4 2027, roughly 12 months away. Positive data would validate PALI-2108's differentiated gut-targeted PDE4 approach in a large, well-controlled study; negative or mixed results would severely impact the stock since PALI-2108 is the company's only clinical-stage asset. Interim milestones to watch include ASCENTRA-CD (Crohn's) first patient dosing targeted for Q1 2027 and any early data presentations at medical conferences.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$2.14
T+0 close · Aug 10, 2026 · via day close
Latest settled
−41.59%
T+60 · $1.25
Vs SPY
−41.10%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 11 $2.14entry
  2. T+1 · 3mo ago −8.41%α −8.66% · $1.96
  3. T+5 · 3mo ago −4.67%α −4.27% · $2.04
  4. T+20 · 2mo ago −4.21%α −3.15% · $2.05
  5. T+60 · 13d ago −41.59%α −41.10% · $1.25
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Palisade Bio reported Q2 2026 results in line with Street consensus (EPS -$0.05 vs -$0.05 est), with no revenue surprise. The filing is dominated by operational progress, FDA IND clearance, Phase 2 ASCENTRA-UC trial commencement expected in 2H 2026, and a strong $125.2M cash position funding through key Phase 2 readouts in 2027-2028. The $0.5M milestone license revenue from Newsoara is a modest positive, but the pre-revenue clinical-stage nature of the company makes this a pipeline-progress update rather than a financial catalyst.

Key Financial Metrics

EPS
−$0.05
est −$0.05 · 0.0%
Revenue
$500.0K
est $0.00
Rating
in line

Key Facts

  • Net loss of $10.6M ($0.05/share) for Q2 2026 vs $2.8M ($0.58/share) in Q2 2025
  • Cash and cash equivalents of $125.2M as of June 30, 2026, down from $133.4M at Dec 31, 2025
  • FDA clearance of IND for Phase 2 ASCENTRA-UC trial of PALI-2108 received; enrollment expected 2H 2026
  • Phase 2 UC primary efficacy readout expected 2H 2027; Phase 2 CD IND expected 2H 2026
  • Recognized $0.5M license revenue milestone from Newsoara co-development agreement
  • Phase 1 data showed 5/5 UC patients achieved clinical response, 2/5 clinical remission; FSCD cohort showed ~47.5% mean SES-CD reduction

Financial Impact

Net loss widened to $10.6M from $2.8M YoY driven by increased R&D ($7.4M vs $1.7M) and G&A ($4.8M vs $1.2M) expenses as the company scales for Phase 2. Cash burn of $8.2M in H1 2026 vs $4.4M in H1 2025. $125.2M cash runway sufficient through Phase 2 readouts.

net losscash and cash equivalentsoperating expenseslicense revenue

Risk Factors

  • Phase 2 trial failure or disappointing efficacy data
  • Competition from approved IBD therapies (JAK inhibitors, anti-integrins, IL-23 inhibitors)
  • Dilution risk if additional capital needed before Phase 2 readouts
  • Small Phase 1 sample size (n=5 per cohort) may not predict Phase 2 results

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
94% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001357459-26-000017
Document: pali-20260810.htm0001357459-26-000017
Document: 0001357459-26-000017-index-headers.html0001357459-26-000017
Document: 0001357459-26-000017-index.html0001357459-26-000017
Document: 0001357459-26-000017.txt0001357459-26-000017
8-K Data (Synthetic)0001357459-26-000017

Track record

14 reports on PALI

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.08 Now $1.03 −4.19% settles Dec 15
  2. Nov 10, 20266d ago 8-K Neutral 5/10 Entry $1.17 Now $1.03 −11.97% settles Dec 10
  3. Nov 9, 20267d ago SC 13G/A Neutral 3/10 Entry $1.13 Now $1.03 −8.85% settles Dec 9
  4. Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $1.16 Now $1.03 −11.21% settles Nov 30
  5. Sep 22, 20267w ago Institutional Cluster Mixed 4/10 Entry $1.69 to $1.43 Now $1.03 −39.05% ▼ −15.38% −14.82% vs SPY
  6. Sep 22, 20267w ago Press Release Bullish 6/10 Entry $1.69 to $1.43 Now $1.03 −39.05% ▼ −15.38% −14.82% vs SPY
  7. Aug 10, 202614w ago 8-K Neutral 5/10 Viewing Entry $2.14 to $2.05 Now $1.03 −51.87% ▼ −4.21% −3.15% vs SPY
  8. Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $1.89 to $2.10 Now $1.03 −45.50% ▲ +11.11% +7.93% vs SPY
  9. Jul 8, 202618w ago Insider Cluster Neutral 3/10 Entry $1.97 to $2.09 Now $1.03 −47.72% ▲ +6.09% +3.85% vs SPY
  10. Jun 11, 202622w ago 8-K Neutral 4/10 Entry $1.71 to $1.96 Now $1.03 −39.77% ▲ +14.62% +12.84% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026